PuraMed to expand product line by developing hemp, THC-free cannabis formulations

Initially, the company aims to develop and manufacture hemp and THC-free formulations that create medicinal compounds that don’t produce the ‘high’ associated with cannabis containing THC.

Scientific research has demonstrated that cannabinoids can be formulated to effectively treat conditions such as multiple sclerosis, Crohn’s disease, pain, neurodegenerative disorders, epilepsy, arthritis and combat the effects of cancer chemotherapy.

PuraMed BioScience CEO Russell Mitchell said integrating cannabinoid-based medications into the company’s product line makes sense with what we are already doing.

"Cannabis has been used medicinally for centuries. It has only been in the last 100 years that its schedule 1 drug status and the abuse of this product for non-medicinal purposes has detracted from its medicinal benefits," Mitchell said.

"Medical journal publication sites list many medical articles that report cannabinoids provide a viable treatment to neurologic problems, inflammatory diseases, and pain.

"Due to recent changes in the legality and availability of cannabinoids, we believe the future looks extremely bright for the development of highly effective and safe treatments incorporating these hemp derived compounds."

The company said that results of its preliminary research combined with the fact that the US cannabis market is expected to grow to over $10bn by 2018, are strong reasons to aggressively develop a cannabis and hemp-based product line.

Development of these products will continue the company’s mission of providing safe, effective products that use natural ingredients.